Brussels (Belgium), 8th March 2022, 07:00 (CET) – UCB, a global biopharmaceutical company, today announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine l’Alleud, Wallonia, Belgium. The new facility, representing an investment of more than 200 million euros over the coming years, is expected to be operational in 2024. Construction is due to start in the second quarter of 2022.

Brussels (Belgium) 02 February 2022 – 07:00 (CET): – UCB, a global biopharmaceutical company, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for BRIVIACT® (brivaracetam) and Vimpat® (lacosamide) to treat partial onset seizures with or without secondary generalization in patients from two to four years of age.3,4

Brussels, Belgium and Atlanta, Ga. – February 04, 2022 – 07:00 CET: Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) trial1 evaluating its investigational treatment zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor), versus placebo in adults with generalized myasthenia gravis (gMG).

UCB Full-Year Report 2021, Brussels (Belgium), 24 February 2022 – 7:00 (CET) – regulated information Jean-Christophe Tellier, CEO UCB says: “We are very satisfied with the continued performance of UCB – we reached more than 3.7 million patients. We are entering a transition phase, to be followed by accelerated company growth, from a position of strength – also underlined by six very positive Phase 3 study read-outs from our late-stage pipeline. We thank our employees and partners for their great contributions. The coming months will be marked by expected impacts from the loss of exclusivity for E KEPPRA® in Japan since January, for VIMPAT® in the U.S. in March and the EU in September. We are confident to bring BIMZELX® to people living with psoriasis in the U.S. based on a regulatory decision expected within the first half this year. We continue to make progress towards our extra-financial targets, also recognized by key ESG ratings. We are very confident in our strong growth ahead and our ability in creating value for all stakeholders – now and into the future.”

Brussels (Belgium) and Emeryville, CA (USA), 19 January 2022 - Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine for treatment of Lennox-Gastaut syndrome (LGS). The upfront consideration represents a 72% premium to Zogenix shares based on the 30-day volume weighted average closing stock price of Zogenix prior to signing. The total transaction is valued at up to approximately US$ 1.9 billion / € 1.7 billion.

Brussels, Belgium – 21st January 2022 – 07:00 CET – Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the efficacy and safety of BIMZELX® (bimekizumab) in the treatment of adults with active psoriatic arthritis, who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy.1

Brussels, Belgium – 18th January 2022 – 07:00 CET – Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints.1 BE MOBILE 1 is the first study to evaluate the efficacy and safety of BIMZELX® (bimekizumab) in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Brussels, Belgium and Atlanta, Ga. – August 7th, 2021 – 20:00 CEST/14:00 EST – UCB, a global biopharmaceutical company, announced today new interim data from BE BRIGHT, an open-label extension (OLE) trial to assess the long-term safety, tolerability and efficacy of bimekizumab, an investigational IL-17A and IL-17F inhibitor, in adults with moderate to severe plaque psoriasis.[i],[ii] These results were presented today during a platform presentation at the 2021 American Academy of Dermatology (AAD) Summer Meeting, Tampa, Florida, U.S.

UCB and Microsoft have announced a new multi-year, strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with UCB’s drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets or multi-modal unstructured information, Microsoft’s platform can support UCB’s scientists, including its data scientists, to discover new medicines in a more efficient and innovative way.

Brussels, Belgium – EMBARGOED FOR RELEASE: February 4, 2021, 23:30 PM GMT – UCB, a global biopharmaceutical company, today announced that The Lancet has published results from BE VIVID and BE READY, two Phase 3 studies evaluating the efficacy and safety profile of bimekizumab, its investigational IL-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis.1,2 The manuscripts of these two studies, published back to back, are the first publications from the Phase 3 clinical development program of bimekizumab in psoriasis. A comment piece accompanying these manuscripts is also published today.

Brussels (Belgium) January 28, 2021 – 7:00 CET – Launched in June 2020, the UCB Community Health Fund directs funds to 50 impact-driven organizations and projects aiming to understand and reduce the medium- and long-term impact of the COVID-19 pandemic on the health of vulnerable young people.

Brussels (Belgium) and Atlanta, Ga. 13 January 2021 – 7:00a (CET) - UCB today announced the launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers (HCPs). Nile was founded with a clear mission in mind: to make the journey of every epilepsy patient predictable. To that end, Nile is developing an epilepsy care management platform that serves as a digital extension of the healthcare provider (HCP) and provides patients with peace of mind between consultations, with the ultimate goal of shortening the path to optimal treatment.

BRUSSELS, BELGIUM (12th November 2020, 07:00 CET) – UCB today announced the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium and a new collaboration with Lacerta Therapeutics, a Florida based clinical stage gene therapy company. The new acquisition and collaboration will together serve to rapidly accelerate UCB’s ambition in gene therapy.

Brussels, Belgium, Atlanta, Ga., November 17, 2020: UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VIMPAT® (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older and VIMPAT injection for intravenous use in children four years of age and older.1 PGTCS is a type of seizure that occurs all over the brain, affecting both sides of the brain from the start, causing muscles to stiffen and convulsions to occur for up to a few minutes.2

Brussels, Belgium – October 31, 2020 – UCB, a global biopharmaceutical company, today announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate-to-severe plaque psoriasis.1 These findings were presented for the first time as an oral presentation at the European Academy of Dermatology and Venereology Congress, taking place virtually between October 29-31, 2020.

Brussels (Belgium) 29 July 2020 – 7:00 (CEST) - UCB today announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD). The transaction remains subject to obtaining antitrust clearance and other customary closing conditions.

Bruxelles (Belgique), lundi 27 juillet 2020 – 07:00 (CEST) – information réglementée – UCB - Rapport semestriel 2020

Brussels (Belgium), 3 July 2020 – 20:00 (CEST) – regulated information

Brussels (Belgium) 05 June 2020 – 7:00 (CEST) - regulated information – inside information – UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a clinical-stage pharmaceutical company developing Staccato®Alprazolam for the rapid termination of an active epileptic seizure, for US$ 125 million in cash (subject to certain adjustments) and up to US$ 145 million in further potential milestone payments related to clinical development, submission and launch of Staccato® Alprazolam.

Brussels (Belgium), 2 June 2020 – 20:00 (CEST) – regulated information. In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2020.